Metastatic Prostate Cancer

被引：388

作者：

Sartor, Oliver ^{[1
]}

de Bono, Johann S. ^{[2
,3
]}

机构：

[1] Tulane Med Sch, New Orleans, LA USA

[2] Inst Canc Res, London, England

[3] Royal Marsden NHS Fdn Trust, London, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 07期

关键词：

POST HOC ANALYSIS; ABIRATERONE ACETATE; PHASE-III; RADIOGRAPHIC PROGRESSION; 1ST-LINE CHEMOTHERAPY; INCREASED SURVIVAL; PROGNOSTIC MODEL; PLUS PREDNISONE; CLINICAL-TRIAL; CASTRATION;

D O I：

10.1056/NEJMra1701695

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Care for men with prostate cancer is a major global health care challenge, compounded by an aging population and increasing frequency of diagnosis. The priorities today are similar to those in the recent past: minimizing overtreatment of indolent disease and improving outcomes for patients with aggressive disease. Herein we focus on recent accomplishments and future challenges in the management of metastatic disease, which continues to be associated with a high rate of death despite multiple new-drug approvals in recent years. Metastatic prostate cancer can be broadly divided into two groups: disease that has not been treated with androgen deprivation and disease that is resistant to such therapy. Treating metastatic prostate cancer is becomingly increasingly complex. We review studies that are changing the standard of care, and we offer a conceptual perspective for addressing ongoing challenges and opportunities. Copyright © 2018 Massachusetts Medical Society.

引用

页码：645 / 657

页数：13

共 76 条

[1]

[Anonymous], 2016, Ann Oncol, DOI [10.1093/annonc/mdw372.09, DOI 10.1093/ANNONC/MDW372.09]

[2] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Nakazawa, Mary ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JAMA ONCOLOGY, 2015, 1 (05) :582-591

[3] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[4] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[5] A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC). [J].

Attard, Gerhardt ;

Borre, Michael ;

Gurney, Howard ;

Loriot, Yohann ;

Andresen, Corina ;

Kalleda, Ranjith ;

Pham, Trinh ;

Taplin, Mary-Ellen .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[6] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[7] Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic [J].

Auchus, Richard J. .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 165 :71-78

[8] Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer [J].

Barbieri, Christopher E. ;

Baca, Sylvan C. ;

Lawrence, Michael S. ;

Demichelis, Francesca ;

Blattner, Mirjam ;

Theurillat, Jean-Philippe ;

White, Thomas A. ;

Stojanov, Petar ;

Van Allen, Eliezer ;

Stransky, Nicolas ;

Nickerson, Elizabeth ;

Chae, Sung-Suk ;

Boysen, Gunther ;

Auclair, Daniel ;

Onofrio, Robert C. ;

Park, Kyung ;

Kitabayashi, Naoki ;

MacDonald, Theresa Y. ;

Sheikh, Karen ;

Vuong, Terry ;

Guiducci, Candace ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Carter, Scott L. ;

Saksena, Gordon ;

Voet, Douglas ;

Hussain, Wasay M. ;

Ramos, Alex H. ;

Winckler, Wendy ;

Redman, Michelle C. ;

Ardlie, Kristin ;

Tewari, Ashutosh K. ;

Mosquera, Juan Miguel ;

Rupp, Niels ;

Wild, Peter J. ;

Moch, Holger ;

Morrissey, Colm ;

Nelson, Peter S. ;

Kantoff, Philip W. ;

Gabriel, Stacey B. ;

Golub, Todd R. ;

Meyerson, Matthew ;

Lander, Eric S. ;

Getz, Gad ;

Rubin, Mark A. ;

Garraway, Levi A. .

NATURE GENETICS, 2012, 44 (06) :685-U107

[9]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[10] Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study [J].

Beer, Tomasz M. ;

Armstrong, Andrew J. ;

Rathkopf, Dana ;

Loriot, Yohann ;

Sternberg, Cora N. ;

Higano, Celestia S. ;

Iversen, Peter ;

Evans, Christopher P. ;

Kim, Choung-Soo ;

Kimura, Go ;

Miller, Kurt ;

Saad, Fred ;

Bjartell, Anders S. ;

Borre, Michael ;

Mulders, Peter ;

Tammela, Teuvo L. ;

Parli, Teresa ;

Sari, Suha ;

van Os, Steve ;

Theeuwes, Ad ;

Tombal, Bertrand .

EUROPEAN UROLOGY, 2017, 71 (02) :151-154

← 1 2 3 4 5 6 7 8 →